Genmab
Genmab is the Danish antibody engineering company behind the DuoBody platform, Tivdak, Epkinly, and (via ProfoundBio) rinatabart sesutecan.
Tisotumab vedotin, epcoritamab (CD20×CD3), rinatabart sesutecan (FRα ADC, phase 3), acasunlimab (PD-L1×4-1BB). DuoBody technology underlies teclistamab, talquetamab, amivantamab.
Tisotumab vedotin is an ADC against tissue factor, the first to show a survival benefit in recurrent cervical cancer.
The CD38 antibody that turned triplets into quadruplets: adding it to standard induction roughly halves the risk of myeloma progressing.
Epcoritamab is an under-the-skin injection that pulls T cells onto lymphoma cells; it is approved for relapsed large B-cell and follicular lymphoma, and moving toward first line.
A two-armed antibody that blocks EGFR while gripping LGR5, a marker of cancer stem cells, so it hits the cells that regrow tumours.
Rinatabart sesutecan is a next-generation folate-receptor ADC with a topoisomerase payload that responds in both ovarian and endometrial cancer regardless of receptor level.